0.9902
0.04%
-0.0004
Kronos Bio Inc stock is traded at $0.9902, with a volume of 210.71K.
It is down -0.04% in the last 24 hours and up +3.37% over the past month.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
See More
Previous Close:
$0.9906
Open:
$0.99
24h Volume:
210.71K
Relative Volume:
0.82
Market Cap:
$59.75M
Revenue:
-
Net Income/Loss:
$-112.67M
P/E Ratio:
-0.5078
EPS:
-1.95
Net Cash Flow:
$-79.26M
1W Performance:
+1.04%
1M Performance:
+3.37%
6M Performance:
-20.78%
1Y Performance:
-2.92%
Kronos Bio Inc Stock (KRON) Company Profile
Name
Kronos Bio Inc
Sector
Industry
Phone
(650) 781-5200
Address
1300 S. EL CAMINO REAL, SAN MATEO
Compare KRON with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.9902 | 59.75M | 0 | -112.67M | -79.26M | -1.95 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-14-24 | Downgrade | Piper Sandler | Overweight → Neutral |
Nov-14-24 | Downgrade | TD Cowen | Buy → Hold |
Sep-14-22 | Initiated | Berenberg | Buy |
Oct-20-21 | Resumed | Cowen | Outperform |
Jun-24-21 | Initiated | H.C. Wainwright | Buy |
Nov-03-20 | Initiated | Cowen | Outperform |
Nov-03-20 | Initiated | Goldman | Buy |
Nov-03-20 | Initiated | Jefferies | Buy |
Nov-03-20 | Initiated | Piper Sandler | Overweight |
View All
Kronos Bio Inc Stock (KRON) Latest News
Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Increases By 16.5% - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully - Yahoo Finance
Analyzing Kronos Bio (NASDAQ:KRON) and Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8% – Here’s What Happened - Defense World
Kronos Bio (NASDAQ:KRON) Stock Price Down 1.8%Should You Sell? - MarketBeat
Kronos Bio ends partnership with Genentech By Investing.com - Investing.com Australia
Kronos Bio ends partnership with Genentech - Investing.com India
Kronos Bio Ends Collaboration with Genentech and Roche - TipRanks
Kronos Bio (NASDAQ:KRON) Trading 8.5% HigherHere's Why - MarketBeat
Struggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staff - SFGATE
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - MSN
KRON (Kronos Bio) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
A Look At The Behavior Of Kronos Bio Inc (KRON) Stock - Stocks Register
Kronos Bio announces interim CEO; over 80% of staff reduction - MSN
Kronos Bio announces interim CEO and workforce cuts of 83% - Yahoo Finance
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up - MSN
Strategic shift at Kronos creates CEO vacancy - The Pharma Letter
Kronos Bio to lay off 83% of staff as CEO steps down - The Business Journals
Kronos Bio announces layoffs and executive changes By Investing.com - Investing.com Nigeria
Kronos Bio, Inc. Announces Management Changes, Effective December 3, 2024 - Marketscreener.com
Kronos Bio, Inc. Announces CEO Changes, Effective December 3, 2024 - Marketscreener.com
Kronos Bio Shakes Up LeadershipCuts 83% Of Workforce Amid Strategic Overhaul - AOL
Biotech with Cambridge lab slashes 83% of staff, CEO departs - NBC Boston
Kronos Bio announces layoffs and executive changes - Investing.com India
Kronos Bio Announces CEO Transition and Reduction in Force - The Manila Times
Kronos Bio stock in focus on CEO change, layoffs (KRON:NASDAQ) - Seeking Alpha
Kronos Bio to Cut 83% Of Workforce, Names Interim CEO - MarketWatch
Kronos Bio Cuts 83% of Workforce, Names New CEO Amid Strategic Review | KRON Stock News - StockTitan
Kronos Bio Restructures Workforce and Leadership - TipRanks
Kronos Bio : Management Change/Compensation Form 8 K - Marketscreener.com
Kronos, Idorsia plan layoffs; PTC shelves ALS drug - Yahoo Finance
KRON (Kronos Bio) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Kronos Bio Inc Stock (KRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):